Multiple Catalysts Ahead For Nektar Therapeutics
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Outsourcing-pharma2d
Private equity firms GHO and Ampersand acquire Avid Bioservices for $1.1 billion
For Ampersand, the Avid deal closely follows the acquisition of Nektar Therapeutics’ commercial-scale manufacturing facility ...
Targeted Oncology4d
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC
NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Nektar Therapeutics Reports Stable Q3 Earnings for 2024
Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...
BioPharma Dive6d
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook
Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...
Le Lézard6d
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...
Nektar: Q3 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...